Abstract | Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disease and is responsible for 5-10% of cases of end-stage renal disease worldwide. ADPKD is characterized by the relentless development and growth of cysts, which cause progressive kidney enlargement associated with hypertension, pain, reduced quality of life and eventual kidney failure. Mutations in the PKD1 or PKD2 genes, which encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively, cause ADPKD. However, neither the functions of these proteins nor the molecular mechanisms of ADPKD pathogenesis are well understood. Here, we review the literature that examines how reduced levels of functional PC1 or PC2 at the primary cilia and/or the endoplasmic reticulum directly disrupts intracellular calcium signalling and indirectly disrupts calcium-regulated cAMP and purinergic signalling. We propose a hypothetical model in which dysregulated metabolism of cAMP and purinergic signalling increases the sensitivity of principal cells in collecting ducts and of tubular epithelial cells in the distal nephron to the constant tonic action of vasopressin. The resulting magnified response to vasopressin further enhances the disruption of calcium signalling that is initiated by mutations in PC1 or PC2, and activates downstream signalling pathways that cause impaired tubulogenesis, increased cell proliferation, increased fluid secretion and interstitial inflammation.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disease and the fourth leading cause of end-stage renal disease; it is responsible for 5-10% of cases of end-stage renal disease globally. 1, 2 It affects all ethnic groups and is a major burden on public health services. 3, 4 The disease is genetically heterogeneous, and caused by mutations at two genetic loci: PKD1 (16p13.3), which encodes polycystin-1 (PC1), and PKD2 (4q22), which encodes polycystin-2 (PC2). [5] [6] [7] [8] The disease is characterized by the relentless development and growth of cysts, which cause progressive kidney enlargement associ ated with hypertension, abdominal fullness and pain, episodes of cyst haemorrhage, gross haematuria, nephro lithiasis, cyst infections and reduced quality of life. 1, 2 Despite continuous destruction of the parenchyma in ADPKD, compensatory hyperfiltration of the surviving glomeruli maintains renal function within the normal range for decades. 9, 10 Only when the majority of nephrons have been destroyed does renal function decline, typically after the fourth decade of life; end-stage renal disease ensues in the majority of patients. 9, 10 Medical advances have improved the treatment of ADPKD but therapeutic approaches remain restricted to the detection and treatment of complications, and eventually renal replacement therapy. Research into poly cystic kidney disease (PKD) increased exponentially after the discovery of PKD1 and PKD2 in 1994 and 1996, respectively. Targets for intervention have been identified and therapies tested in animal models, with some clinical trials providing modest but encouraging results. [11] [12] Nevertheless, the functions of the polycystins and the molecular mechanisms responsible for the development of PKD remain poorly understood, and better therapies are needed.
The objective of this Review is to synthesize the large body of literature that examines how reduced levels of functional PC1 or PC2 directly disrupt calcium signalling at specific cellular compartments-the primary cilia and/or the endoplasmic reticulum (ER)-and indirectly disrupt calcium-regulated cAMP and purinergic signalling. We propose a hypothetical model in which dysregulated cAMP metabolism and purinergic signalling increase the sensitivity of principal cells in collecting ducts and of tubular epithelial cells in the distal nephron to the continuous tonic action of vasopressin. This effect further enhances the disruption of calcium signalling that is initiated by mutations in PKD1 or PKD2, and activates downstream signalling pathways that are responsible for impaired tubulogenesis, cell proliferation, increased fluid secretion and interstitial inflammation. Results of in vivo studies that address the role of calcium and cAMP in PKD are consistent with this hypothetical model. The sections below examine the components of this hypothesis in detail, and Figure 1 illustrates the hypothesis.
Disrupted calcium signalling in PKD
Polycystins and calcium signalling PC1 (which has 4,303 amino acids and a molecular weight of ~600 kDa when uncleaved and glycosy lated) is a receptor-like protein with a large extracellular region (3,074 amino acids), which comprises a number of domains that are involved in protein-protein and protein-carbohydrate interactions ( Figure 2 ). The protein also has 11 transmembrane domains and a cytoplasmic tail. The last six transmembrane domains of PC1 are homologous in sequence with PC2, although no evidence exists to suggest that PC1 functions as a channel, as PC2 does. Autoproteolytic cleavage of PC1 at the G-proteincoupled receptor proteolytic site domain is important in the formation of the functional protein. [14] [15] [16] After embryonic development, most PC1 is cleaved into one ~130 kDa C-terminal product (CT) and two large N-terminal products (NT), although CT and NT are thought to remain associated with each other. The two NT products are glycoforms: one is a mature form that traffics through the Golgi apparatus and is thought to be either secreted or localized to the plasma membrane or cilia; the other might be retained in the ER. [17] [18] [19] Evidence suggests that PC1 is cleaved a further three times, with implications for calcium signalling. [20] [21] [22] [23] [24] One cleavage generates P100, an intramembranous fragment that has six membrane-spanning domains and that interacts with stromal interaction molecule 1 (STIM1) to inhibit store-operated calcium entry. 20 The other cleavage events generate two COOH-terminal tail (CTT) fragments with molecular weights of 35 kDa and 17 kDa. The 35 kDa fragment can enter the nucleus and bind to two transcription factors (T-cell factor and CCAAT/ enhancer-binding protein homologous protein) to prevent their interaction with the transcriptional coactivator histone acetyltransferase p300. [21] [22] [23] The 17 kDa fragment binds to p100 coactivator and activates the transcription factor STAT6. 24 The importance of these CCT fragments to the pathogenesis of ADPKD has not been elucidated. Several studies have used exo genous expression of chimeric proteins that contain the CTT of PC1 fused to a membrane-targeted protein. The results of these studies are difficult to interpret: in some cases they might recapitulate the function of the native protein, whereas in other cases they might have dominant negative effects (Table 1) . [25] [26] [27] [28] [29] [30] [31] [32] PC2 (which has 968 amino acids and a molecular weight of ~110 kDa) is a large-conductance, calciumpermeable, non-selective cation channel that has six transmembrane domains and belongs to the transient receptor potential (TRP) family.
33,34 PC1 and PC2 interact via their C-terminal tails. The resulting poly cystin complex is thought to localize to primary cilia and have a role in regulation of intracellular calcium signalling. 14, [35] [36] [37] The interaction of PC2 with PC1 is also important for the translocation of PC2 to the plasma membrane and to primary cilia; the majority of PC2 is localized to the ER. Some evidence indicates that the interaction is also essential for PC1 maturation. 38, 39 The interactions of PC1 and PC2 with other calcium channel and sensor proteins support the hypothesis that the polycystins have a function in the regulation of intracellular calcium homeostasis. For example, PC1 interacts with the inositol 1,4,5-trisphosphate receptor (IP3R) and STIM1, and PC2 interacts with the IP3R, the ryanodine receptor (RyR), and the channels TRPV4, TRPC1, TRPC3, TRPC4 and TRPC7. [40] [41] [42] [43] [44] [45] [46] [47] Polycystins at the primary cilia Some evidence suggests that a lack of functional polycystins in primary cilia is critical to the pathogenesis of PKD. In Caenorhabditis elegans, a homologue of PC1 (lov-1) and PC2 are found in primary cilia of malespecific sensory neurons, where they mediate male sensory behaviours. 48 Mice that are homozygous for a hypomorphic Ift88
Tg 737Rpw mutation that results in absent or stunted primary cilia have polycystic kidneys. 49 Bending of the primary cilia by fluid flow or directly with a micropipette elicits an intracellular calcium signal. 50 Additional experiments showed that PC1 and PC2, influx of extracellular calcium, and RyR-mediated release of intra cellular calcium together transduce fluid flow shear stress into calcium transients in kidney epithelial cells. 51 These observations led to the cilio centric hypothesis of PKD, according to which PC1 senses bending of the primary cilia and consequently activates tightly associated PC2 calcium channels. The local calcium influx in the cilia was thought to subsequently trigger calciuminduced calcium release from intracellular stores and store-operated calcium entry, with the absence of flow sensing in renal epithelia caused by a lack of polycystin leading to PKD.
Some observations have challenged the validity of this hypothesis. Knockdown of TRPV4, which forms mechano sensitive heteromeric complexes with PC2, abolishes the intracellular calcium response to fluid flow shear stress, but does not result in a cystic phenotype in mice or zebra fish. 46 Use of genetically engineered calcium indicators has shown that primary cilia are specialized calcium signalling organelles that have much higher internal calcium concentrations than does the cytoplasm, but the amount of calcium that can diffuse from the cilia Key points ■ Polycystin-1 and polycystin-2 in the primary cilia and endoplasmic reticulum regulate intracellular calcium signalling; mutations in these proteins cause autosomal dominant polycystic kidney disease (ADPKD) ■ In ADPKD, reduced intracellular calcium increases the generation of and inhibits the destruction of cAMP, and reduces the release of ATP ■ Altered cAMP metabolism and purinergic signalling in collecting duct principal cells and distal nephron epithelial cells markedly increases the sensitivity of these cells to the constant tonic effects of vasopressin ■ Increased protein kinase A activity leads to phosphorylation of polycystin-2, ryanodine receptors and inositol 1,4,5-trisphosphate receptors, increasing leakage of calcium from the endoplasmic reticulum, which further disrupts intracellular calcium signalling ■ The reduction in intracellular calcium that results from mutant polycystin-1 or polycystin-2 causes the cellular response to cAMP to switch from suppression to stimulation of proliferation ■ In vivo studies support the hypothesis that disruption of intracellular calcium signalling has a central role in the pathogenesis of ADPKD to the cytoplasm in response to bending of the cilia is too small to trigger calcium-induced calcium release from intra cellular stores. 52 Changes in calcium concentration in the cilia can be dissociated from those in the cytoplasm, and a lag time between calcium elevation in the cilia and that in the cytoplasm raises the possibility of an intermediate step. 53 The shear stress of flow on epithelial cell mono layers differs from the mechanical effect of flow in isolated perfused tubules; the latter causes stretching in addition to shear stress. 54 Extracellular ATP that acts on purinergic (P2) receptors has emerged as a candidate medi ator of both shear-induced and stretch-induced calcium responses. [54] [55] [56] In a 2013 study that used Madin-Darby canine kidney (MDCK) cells, the intracellular calcium response to shear stress was already present in unciliated cells on culture day 1 and was magnified in ciliated cells on day 7, but this increased response was dependent on increased expression of purinergic P2Y2 and P2X7 receptors rather than on the presence of cilia per se. 57 
Polycystins at the ER and SR
The polycystins, particularly PC2, are found in the ER and sarcoplasmic reticulum (SR) membranes and contribute to the regulation of calcium release from intra cellular stores. A number of studies have aimed to elucidate the role of the polycystins in this process and how it is altered in ADPKD (Tables 2 and 3) . 20, [40] [41] [42] 47, [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] The results of these studies are inconsistent, probably because of different experimental conditions. For example, reduced IP3-induced calcium release has been observed in experiments in which PC1 was knocked down and in experiments in which it was over expressed. 40, 41, 68 Some studies have shown that PC1 or PC2 haploinsufficiency disrupts intracellular calcium homeostasis, [74] [75] [76] particularly in myocytes, 59, 62, 73 whereas others have found no evidence for this disruption. 77 
Studies of polycystin-2 at the ER and SR
Although truncated forms of PC2 that lack the ER and SR retention domain translocate to the plasma membrane, Figure 1 | Hypothetical roles of calcium, vasopressin and purinergic signalling in ADPKD. PC1 and PC2 directly mediate calcium transport and interact with other calcium channel proteins. PC mutations reduce cytosolic calcium levels, which increases vasopressin-dependent production of cAMP via adenylyl cyclase 6 (1), and reduces hydrolysis of cAMP by PDE1. Reduced calcium oscillations inhibit ATP release, abolishing a negative feedback loop that normally limits vasopressindependent cAMP production (2) . Circulating vasopressin levels also increase in response to an impaired urinary concentrating ability that might result from disrupted calcium-dependent insertion of AQP-2 into the apical membrane and/ or disruption of medullary architecture by cysts (3). Vasopressin-driven PKA activation increases phosphorylation of PC2, RyRs and IP3Rs (4), increasing leakage of calcium from the ER and further disrupting calcium signalling. Reduced intracellular calcium switches the response to cAMP from suppression to stimulation of proliferation. Sustained activation of PKA activates downstream pathways that impair tubulogenesis, increase cell proliferation, increase fluid secretion and cause interstitial inflammation characteristic of cystic phenotypes (5 most PC2 is located in the ER and SR membranes. 58 Here, it functions as an ER calcium release channel that is activated by increases in cytosolic calcium concentration. 58 Phosphorylation of PC2 alters its properties as a calcium channel. Constitutive phosphorylation at Ser812 by casein kinase II increases the sensitivity of the channel to calcium on the cytosolic side. 60 Aurora kinase A and protein kinase A (PKA) phosphorylate PC2 at Ser829 and thereby increase the amplitude of ATP-induced calcium release. 70, 71 By contrast, cotransfection of aurora kinase A and PC2 into human embryonic kidney cells reduces the amplitude of vasopressin-induced calcium transients, although the effect of Ser829 phosphorylation in this process has not been directly tested. 71 Physical interactions of PC2 also alter calcium signalling. Syntaxin-5 binds to PC2 and prevents leakage of calcium from ER stores. 65 PC2 also interacts physically and functionally with IP3Rs and RyRs. 42, 47 Most studies have shown that PC2 increases the amplitude of IP3R-mediated and RyR-mediated calcium transients and inhibits leakage of calcium from ER stores, 42 although in one study, exogenous expression of PC2 was associated with increased leakage of calcium from the ER. 67 Another study suggested that the simultaneous presence of PC1 and PC2 is required to amplify IP3-induced calcium release. 68 Interestingly, knockdown of IP3R1 or IP3R3-like the knockdown of PC2-induces cell proliferation, apoptosis and cyst formation in a collagen-matrigel three-dimensional culture system that uses pig kidney epithelial cells. 78 Store-operated calcium entry is also reduced in PC2-defective cells. 42, 59, 63, 65, 79 One study suggested that the interaction between STIM1 (a transmembrane sensor for calcium concentration in the ER lumen) and calcium release-activated calcium channel protein 1 (ORAi; the pore-forming unit of a plasma-membrane channel that permits calcium entry in response to a reduction in the ER calcium concentration) is uncoupled in these cells. 79 
Studies of polycystin-1 at the ER and SR
The function of PC1 in the ER and SR is complex and poorly understood. PC1 interacts with the IP3R and STIM1 in the ER and SR. 20, 40, 41 Exogenous expression of full-length PC1 in MDCK cells decreases the ATP-induced, IP3R-mediated increase in cytosolic calcium. 40 By contrast, the simultaneous presence of PC1 and PC2 was required to elicit IP3-induced calcium release in conditionally immortalized, plasmamembrane-permeabilized human proximal tubule epithelial cells. 68 In another study, PC1 inhibited calcium leakage across the ER membrane. 66 A more complex role in the regulation of calcium release from the ER has also been proposed for PC1, involving its interactions with PC2 and STIM1. 41 Exogenous expression of PC1 reduces the interaction of IP3R with PC2 and enhances the interaction of STIM1 with IP3R, 41 leading to inhibition of ER calcium release, 32 increased PC2 traffic to the plasma membrane that leads to increased entry of extracellular calcium, 29 and inhibition of store-operated calcium entry. 12, 41 According to this model, mutations in PC1 and PC2 lead to depletion of calcium in the ER by different mechanisms. PC1 mutations increase the interaction between PC2 and IP3R, increase calcium release from the ER, and reduce calcium influx through the plasma membrane. PC2 mutations reduce calcium influx across the plasma membrane and enhance the interaction of PC1 and STIM1, thus inhibiting store-operated calcium entry.
Conclusions on polycystins at the ER and SR
Despite the diversity of conclusions reached in the studies of polycystin function at the ER and SR, most findings are consistent with the hypothesis that the polycystinsboth individually and through their interaction with other calcium channels in the ER and SR-prevent the leakage of calcium across the ER and SR membranes and prevent the depletion of intracellular calcium stores, thus maintaining the amplitude of physiological calcium oscillations. 42, 66 Either loss or gain of function might disrupt the physiological role of the polycystins and lead to a cystic phenotype. Cell wall integrity and stress response component LRR Nature Reviews | Nephrology
PC1 PC2
Figure 2 | Predicted structures of PC1 and PC2. PC1 has a large ectodomain that consists of several recognized domains. LRRs are flanked by N-terminal and C-terminal domains, the GPCR proteolysis site is where PC1 is cleaved, and the associated GPCR autoproteolysis-inducing domain consists of A and B subdomains. PC1 has 11 transmembrane domains, and the PC1 lipoxygenase, alpha toxin domain is located in the first cytoplasmic loop. The last six transmembrane domains of PC1 are homologous to the transmembrane region of PC2; the polycystin homologous motifs A and B are found in the large extracellular loops of both proteins. The cytoplasmic tail of PC1 consists of ~200 amino acids and contains a G-protein activating peptide and a CC domain that interacts with CC2 in the C-terminal tail of PC2. PC2 is a TRP-like calcium channel that has an EF-hand and an ER retention signal in the C-terminal tail and a proposed cilia targeting sequence in the N-terminal tail. Abbreviations: CC, coiled-coil; ER, endoplasmic reticulum; GPCR, G-protein-coupled receptor; LRR, leucine-rich repeat; PC, polycystin; TRP, transient receptor potential.
Dysregulation of cAMP signalling
In numerous animal models of PKD, levels of cAMP in the kidney are elevated, 19,84-87 as are levels in cholangiocytes, 88 vascular smooth muscle cells, 89 and the choroid plexus. 90 The activities of membrane-bound and soluble adenylyl cyclases (ACs) and phosphodiesterases (PDEs) determine the levels of cAMP in tissues; both types of enzyme are regulated via complex mechanisms. For example, G-protein-coupled receptors and extracellular ligands can positively and negatively regulate membrane-bound ACs.
Several hypotheses have been advanced to account for the increased levels of cAMP in PKD tissues, most of which involve the dysregulation of intracellular calcium signalling. A prevailing hypothesis argues that reduced calcium in PKD affects both synthesis and hydrolysis of cAMP. Synthesis of cAMP is increased in PKD owing to activation of calcium-inhibitable AC6, whereas cAMP hydrolysis is decreased owing to inhibition of calciumcalmodulin-dependent PDE1. 85, 89, 91 Levels of cGMP also increase with limited PDE1 activity and contribute to elevated cAMP levels by inhibiting cGMP-inhibitable PDE3 (Figure 1 ). The importance of AC6 in the pathogenesis of PKD is demonstrated by the fact that mice with both Adcy6 and Pkd1 specifically knocked out in the collecting duct have milder cystic disease than do mice with Pkd1 alone deleted. 92 Several lines of evidence support a role for PDE1 in PKD. Pronephric cysts, hydrocephalus, and body curvature are induced in pde1a zebra fish morphants, and this phenotype is rescued by injection of human PDE1A RNA or PKA inhibitors. 93 Furthermore, morpholino-induced depletion of PDE1 exacerbates the cystic phenotype of pkd2 zebra fish morphants, and the pkd2 morphant phenotype is partially rescued by injection of PDE1A RNA. 93 Also of note is that PDE1 is largely responsible for the hydrolysis of the pool of cAMP that is generated in response to vasopressin; when intra cellular calcium is reduced-mainly as a result of reduced PDE1 activityaccumulation of cAMP in response to vasopressin is markedly increased (Figure 1) . 94, 95 PDE3 might also be involved in the regulation of cAMP signalling. This enzyme localizes to ER membranes 96, 97 and catabolizes pools of cAMP that control cell proliferation [98] [99] [100] and chloride secretion, which is driven by cystic fibrosis transmembrane conductance regulator (CFTR). 101, 102 Two further hypothetical mechanisms in which disruption of calcium signalling upregulates cAMP signalling have been suggested. One proposes that a decrease in PC2-mediated calcium entry activates AC5 and/ or AC6 and inhibits PDE4C owing to dysfunction of a ciliary protein complex that comprises A-kinase anchoring protein 150, AC5, AC6, PC2, PDE4C and PKA. 103 The other proposes that depletion of ER calcium stores leads to STIM1 oligomerization and translocation to the plasma membrane, where it recruits and activates AC6. 79 Dysregulation of purinergic signalling Renal tubular epithelial cells, like neuronal and neuroendocrine cells, exhibit constitutive ATP release and spontaneous calcium oscillations. [54] [55] [56] These two processes are reciprocally regulated: ATP release occurs by calcium-dependent vesicular exocytosis, and calcium oscillations are abolished by ATP scavengers or P2 receptor antagonists.
ATP acts on ligand-gated P2X receptors and on G-protein-coupled P2Y receptors; 54 P2Y2 and P2X7 are expressed in collecting ducts and in MDCK cells. P2X receptors are calcium-permeable, nonselective cation channels that, when activated, increase intracellular calcium. P2Y receptors are Gq-phospholipase C-coupled receptors; phospholipase C cleaves phosphatidylinositol 4,5-bisphosphate into IP3 and diacylglycerol. IP3 acts on IP3R to release calcium, and diacylglycerol activates protein kinase C ( Figure 1 , and discussed in greater detail below). P2 receptors require a concentration of extracellular nucleotides of ~1-10 μM for full activation. Such elevated concentrations of released ATP probably exist close to the cell membrane in healthy conditions. Primary and immortalized ADPKD cyst cells exhibit markedly reduced flow-sensitive ATP release. 104 Furthermore, the intracellular calcium response to exogenously applied ATP is moderately reduced in immortalized ADPKD cyst cells, 104 possibly as a result of reduced P2X7 mRNA and protein levels, as also observed in immature, unciliated MDCK cells. 57 ATP release in response to shear stress is also reduced in collecting duct principal cells that are derived from an Oak Ridge Polycystic Kidney mouse model and that lack normal apical cilia. 105 Knockdown of PC2 markedly blunts the ATP-dependent increase in PKA phosphorylates PC2 at Ser829; PC1 facilitates dephosphorylation of Ser829 via interaction with PC2 and PP1α; PC2 Ser829 phosphorylation is increased in cystic human and mouse tissue; phosphorylation of PC2 at Ser829 is necessary to rescue a pkd2 knockdown phenotype in Xenopus; phosphomimic PC2 Ser829Asp mutant leads to increased ATP-stimulated Ca 2+ transients and loss of growth suppression; PC2 hyperphosphorylation might contribute to cystogenesis Abbreviations: CHO, Chinese hamster ovary; ER, endoplasmic reticulum; HEK, human embryonic kidney; HeLa, Henrietta Lacks; IP3, inositol 1,4,5-trisphosphate; IP3R, IP3 receptor; LLC-PK1, Lilly Laboratories cell-porcine kidney; MDCK, Madin-Darby canine kidney; PC, polycystin; PP1α, protein phosphatase-1α; SERCA, sarcoendoplasmic reticulum calcium transport ATPase; STIM1, stromal interaction molecule 1; TM, transmembrane; TRP, transient receptor potential channel; UV, ultraviolet; VSMC, vascular smooth muscle cell; WT, wild-type. intracellular calcium that is elicited by shear stress or by mechanical stretch in endothelial cells. 106 Therefore, the defective release of ATP in ADPKD-derived cyst cells is a plausible, but not proven, consequence of the altered intracellular calcium homeostasis in PKD.
The central role of vasopressin in PKD
Constant tonic action of vasopressin on V2 receptors is a legacy of terrestrial adaptation in tetrapods. This effect is greater in patients with ADPKD because their circulating levels of vasopressin are often higher than normal. [107] [108] [109] Elevated plasma levels of copeptin-a surrogate for vasopressin-have also been observed in patients with ADPKD compared with levels in healthy kidney donors, despite higher glomerular filtration rates in patients with ADPKD. 110 Furthermore, plasma copeptin levels correlate with the severity of PKD in crosssectional studies and with the rate of disease progression in prospective studies.
111-113

Mechanisms of vasopressin elevation
The cause of the elevated levels of vasopressin and copeptin is thought to be impaired urinary concentrating capacity, which is one of the earliest manifestations of ADPKD: it can be detected in patients with normal glomerular filtration rate and even in children with ADPKD. 107, 114 However, the cause of this concentrating defect has not been fully elucidated. The defect cannot be explained by reductions in cAMP generation or expression of aquaporin-2, as both cAMP level and aquaporin-2 expression are increased in animal models of PKD. 85, 115, 116 Urinary concentrating capacity is not reduced-sometimes it is even slightly increased-in heterozygous Pkd1 +/-mice, which have few renal cysts. 76 By contrast, in a rapidly progressive congenital polycystic kidney mouse model of PKD, polyuria develops with overexpression of genes that are involved in urinary concentration in collecting ducts, and this overexpression precedes the development of cysts. 115 Similarly, in diphenyl amine-induced or diphenylthiazole-induced models of PKD, polyuria occurs before collecting duct dilation. 117, 118 Additionally, renal ciliopathies in which macroscopic cysts feature less prominently than in ADPKD, such as autosomal recessive PKD (ARPKD), nephronophthisis and Bardet-Biedl syndrome, are also characterized by early development of impaired urinary concentrating capa city. 119, 120 Some studies have shown an abnormal intra cellular distribution of aquaporin-2 in ADPKD, suggesting that its trafficking or recycling is altered in PKD (Figure 1) . 115, 121 Overall, the most likely cause of the urinary concentrating defect is an alteration of molecular pathways within collecting duct cells together with cystic distortion of the countercurrent mechanism.
Vasopressin and cAMP signalling Studies in the past decade have shown that the development of PKD is strongly modulated by circulating vasopressin that acts on vasopressin V2 receptors in the basolateral cell membranes and/or (to a lesser extent) by urinary vasopressin that acts on V2 receptors in the primary cilia. Administration of the V2 receptor agonist DDAVP increases renal levels of cAMP (because vasopressin is the main agonist of AC in freshly dissociated collecting ducts 122 ) and exacerbates the development of PKD in rodent models of both ARPKD (for example, the PCK rat) or of ADPKD that is caused by mutations in Pkd1 (Pkd1 RC/RC mouse) or Pkd2 (Pkd2 WS25/-mouse). 123 Genetic elimination of circulating vasopressin markedly inhibits the development of renal cystic disease in the PCK rat, and exogenous administration of DDAVP fully reinstates the cystic phenotype.
124
Vasopressin V2-receptor antagonists inhibit the development of disease in five rodent models of human ARPKD, ADPKD and nephronophthisis. 85, 116, [125] [126] [127] In addition, a randomized double-blind placebocontrolled clinical trial that involved patients aged 18-50 years with ADPKD showed a slower increase in kidney volume, a smaller decline in kidney function, and a lower frequency of disease-related events in patients that received the V2-receptor antagonist tolvaptan over 3 years compared with patients who received a placebo. Baseline estimated creatinine clearance in patients was ≥60 ml/min, and baseline total kidney volume was ≥750 ml.
11
Vasopressin and purinergic signalling Physiological concentrations of vasopressin induce RyR-dependent calcium oscillations in inner medullary collecting duct cells that result in trafficking and exocytotic insertion of aquaporin-2 into the apical membrane, and release of ATP in sufficient concentrations to stimulate the luminal P2 receptors. 128, 129 Vasopressin V2-receptor antagonists reduce the urinary concentration of ATP in mice. 130 The release of ATP might normally initiate a negative feedback loop that limits the effect of vasopressin, as ATP inhibits an increase in water permeability of the collecting duct that is induced by vasopressin. This inhibition results from activation of the phosphoinositide signalling pathway that leads to activation of PKC and Gi (Figure 1) . 131, 132 Calcium-dependent activation of phospholipase A2 might also have a role; this activation results in increased production of prostaglandin E2 that acts on the prostaglandin E2 receptor EP3 subtype and antagonizes the action of vasopressin on the medullary collecting duct. 133, 134 Genetic deletion of the P2Y2 receptor increases expression of aquaporin-2, urea transporter A1 and urea transporter A2, and increases urine concentration, both under basal conditions and following administration of vasopressin. 135 Purinergic signalling also provides local paracrine regulation of vasopressin and tonically inhibits its effect. 135 This feedback mechanism might be defective in the cystic epithelium, leading to further upregulation of cAMP and PKA signalling, which, in the setting of reduced intra cellular calcium, would lead to the proliferative and secretory phenotype of the cystic epithelium.
Self-perpetuation of disruption
Although dysregulation of intracellular calcium homeostasis that directly results from mutated PC1 or PC2 might be responsible for upregulation of cAMP and PKA signalling, subsequent sustained activation of PKA could result in a maladaptive response that further disrupts calcium signalling. PKA is a component of the IP3R macro molecular signalling complex, and PKA phosphorylation of the IP3R increases its channel activity in planar lipid bilayers. 136, 137 PKA is also a component of RyR macro molecular complexes, and PKA phosphorylation of RyR promotes the dissociation of the inhibitory protein calstabin-1, thereby increasing the channel activity. 138, 139 PKA also phosphorylates PC2 and increases the channel's activity. 70 Dephosphorylation of PC2 is mediated by protein phosphatase-1α, which is recruited to the polycystin complex by specific binding to PC1; an absence of functional PC1 might, therefore, lead to cAMP-stimulated hyperphosphorylation of PC2, which contributes to the development of cysts in patients with mutations in PKD1. 70 Sustained maladaptive upregulation of cAMP and PKA signalling might lead to hyperphosphorylation of IP3R, RyR and PC2, depletion of ER calcium stores, reduced calcium transients, and development of PKD. Furthermore, the physical interaction of PC2 with RyR2 stabilizes RyR2 in the closed position, and the knockdown of PC2 increases leakage of calcium from the SR, which leads to cardiomyopathy. 69 Thus, PKD might bear some similarity to heart failure and muscle fatigue: 140 in these conditions, leaky RyR2 and RyR1 channelscaused by persistent catecholaminergic stimulation and PKA-induced hyperphosphorylation-leads to depletion of SR calcium stores, [141] [142] [143] causing heart failure or muscle fatigue, respectively.
Downstream effects of disruption
The dysregulation of intracellular calcium and cAMP signalling might be responsible for many features that are characteristic of the cystic phenotype, which are reviewed in detail elsewhere. 144 The cross-talk between calcium and cAMP signalling seems to be particularly important for the control of cell proliferation, and the effect of cAMP on cell proliferation differs between cell types. Whereas cAMP and PKA signalling inhibit cell proliferation in healthy human kidney cortical cells, they activate proproliferative pathways (such as the extracellular signalregulated kinase [ERK] pathway), in cells derived from polycystic kidneys. 145, 146 Application of calcium-channel blockers to healthy human kidney or murine collecting duct cells causes the same proliferative response to cAMP as seen in ADPKD cells. 147 Conversely, calciumelevating treatments (such as calcium-channel activators or ionophores) restore the antimitogenic response to cAMP in cells derived from ADPKD or ARPKD cysts. 148 Thus, overwhelming evidence indicates that intracellular calcium controls the cellular proliferative response to cAMP. Understanding the mechanisms involved is critical to understanding the pathogenesis of PKD.
One study showed that inhibition of calciumdependent phosphatidylinositol 3-kinase (PI3K) activity and downstream inhibition of AKT1 kinase in mouse collecting duct epithelial cells allows activation of protooncogene B-Raf and ERK, and that this activation is dependent on PKA, Src and Ras. 149 Low activity of PI3K and AKT1 when calcium levels are reduced could lead to a proliferative response to cAMP. 149 Consistent with these observations, other studies have shown that knockdown of PC1 or PC2, reduction in intracellular calcium or downregulation of calcium-calmodulin-dependent protein kinase type II (CaMK-II) inhibits AKT1 kinase and activates ERK, 150, 151 and that knockdown of CaMK-II induces pronephric cysts in zebra fish. 149 Similarly, inhibition of PKA-associated proliferation by elevation of intracellular calcium in cholangiocytes derived from PCK rats is dependent on activation of PI3K and AKT1 kinase. 152 On the other hand, increased phosphorylation of PI3K and AKT1 kinase has been observed in cystic tissues from patients and model rodents with PKD. [153] [154] [155] [156] [157] The mammalian target of rapamycin (mTOR) signalling pathway is activated downstream of PKA, 158, 159 and might contribute to PKD by promoting the proliferation of cyst epithelial cells. 160 Activation of mTOR signalling has been linked to upregulation of aerobic glycolysis, a subsequent increase in levels of ATP, and (when combined with ERK-dependent inhibition of liver kinase B1) inhibition of 5'-AMP-activated protein kinase, which normally inhibits mTOR signalling. As a result, mTOR signalling could be further increased. [161] [162] [163] [164] The Wnt-β-catenin signalling pathway might also be involved in the development of PKD, 165 and this pathway is also activated downstream of PKA: increased Wnt-β-catenin signalling follows inhibition of glycogen synthase kinase-3β and stabilization of β-catenin, both of which result from phosphorylation by PKA. [166] [167] [168] PKA-dependent upregulation of several transcription factors also contributes to the increased proliferation of [169] [170] [171] [172] [173] [174] Upregulation of PKA-stimulated, CFTR-mediated, chloride-driven fluid secretion has an important role in the progression of cystic disease. 175, 176 Studies suggest that the calcium-dependent chloride channel anoctamin-1 (ANO1), which is activated via stimulation of Gq-coupled purinergic receptors (P2YR), also has an important role. 177, 178 ANO1 is strongly expressed in human ADPKD kidneys. Inhibition of anoctamin ion channels or knockdown of ANO1 inhibits forskolin-driven cystogenesis in MDCK cell or metanephric organ cultures. Upregulation of CFTR-driven and ANO1-driven chloride secretion might act synergistically downstream of PKA activation, as forskolin stimulates the translocation of ANO1 to the apical membrane and PKA phosphorylation enhances the sensitivity of the IP3R to IP3. The possibility also exists that the relative importance of CFTR-driven and ANO1-driven chloride secretion in PKD depends on the animal species, as it does in cystic fibrosis. 179 In vivo studies of calcium in PKD
The literature reviewed here provides strong support to the prevailing belief that disruption of intracellular calcium signalling has a central role in the pathogenesis of ADPKD. An increasing number of in vivo studies support this view. These studies have focused on the ability of calcium-targeted interventions to modify the course of PKD (Table 4) . 46, [180] [181] [182] [183] [184] 151, [185] [186] [187] [188] [189] Treatments that increase intracellular calcium have, in general, shown a protective effect against development of PKD. cAMP-induced cystogenesis in metanephric organ culture is inhibited by a calcium ionophore. 188 Although the knockout of TRPV4 does not induce a cystic phenotype, TRPV4 activators significantly reduce development of cystic disease in PCK rats. 186, 189 Administration of triptolide-a drug that activates the PC2 channel via a poorly understood mechanism-inhibits development of PKD in Pkd1 -/-embryos and in conditional and kidneyspecific Pkd1-knockout mice. 180, 181, 185 Calcimimetic agents have a beneficial effect in some rodent models of PKD, such as Cy/+ heterozygotic Han:SPRD rats and pcy mice, 183, 187 but no notable effect (except for reduced fibrosis) in others, such as PCK rats and Pkd2 WS25/-mice. In the animals in which no effect was seen, the potential benefit of the drug might have been offset by marked hypocalcaemia. 184, 190 On the other hand, interventions that lower intra cellular calcium levels exacerbate the development of PKD. Administration of verapamil increased development of cysts in Cy/+ heterozygotic Han:SPRD rats.
182 Ca V 1.2 zebra fish morphants have dilated pronephric ducts, 151 and lentiviral transfection of Ca V 1.2 small hairpin RNA exacerbates the cystic phenotype in Pkd1 +/-mice. 151 Conclusions ADPKD, a leading cause of end-stage renal disease, is caused by mutations to PKD1 or PKD2 that encode PC1 and PC2, respectively. The function of the polycystins and the molecular mechanisms responsible for the development of the disease are not well understood. Substantial evidence indicates that a reduction of functional PC1 or PC2 at the primary cilia and/or the ER directly disrupts intracellular calcium signalling and indirectly disrupts calcium-regulated cAMP and purinergic signalling. This Review presents a hypothetical model in which dysregulated metabolism of cAMP and purinergic signalling increases the sensitivity of principal cells in collecting ducts and of tubular epithelial cells in the distal nephron to the constant tonic action of vasopressin, thereby further enhancing the disruption of calcium signalling that is initiated by mutations in PKD1 or PKD2. The consequence is activation of downstream signalling pathways that are responsible for impaired tubulogenesis, increased cell proliferation, increased fluid secretion and interstitial inflammation. Alterations in calcium and cAMP signalling are proximate to the root cause of ADPKD, so treatments that target them individually or in combination are likely to be more effective than interventions that act on more distant downstream pathways, and warrant further study. 
